Company Overview and News

NMI Holdings started at outperform with $18 stock price target at RBC Capital

2018-04-19 marketwatch
Greenlight Capital's (GLRE) new innovation unit, Greenlight Re, is expected to amp up its efficiency and quality of products and services available to its clients.
Upvote Downvote

Should iShares Edge MSCI Multifactor USA ETF (LRGF) Be on Your Investing Radar?

2018-04-18 zacks
If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the iShares Edge MSCI Multifactor USA ETF (LRGF - Free Report) , a passively managed exchange traded fund launched on 04/28/2015.
Upvote Downvote

UnitedHealth earnings ease investor worries over flu season, stock up

2018-04-17 channelnewsasia
UnitedHealth Group Inc on Tuesday posted a quarterly profit that beat Wall Street estimates, fueled by growth in its core insurance and health-services businesses and raised its earnings forecast for the year.
Upvote Downvote

UnitedHealth (UNH) Q1 Earnings to Gain From Optum Revenues

2018-04-16 zacks
We believe UnitedHealth Group Inc.’s (UNH - Free Report) health services business Optum will be an important ingredient of its first-quarter earnings growth. Optum serves the global healthcare marketplace, including payers, care providers, employers, governments, life sciences companies and consumers. The company is investing in this segment with an aim to diversify earnings and seek protection from the highly regulated health services business.
Upvote Downvote

It Might Be Time to Take Profits in Humana Inc Stock

2018-04-06 investorplace
As the old saw on Wall Street goes, pigs get fed and hogs get slaughtered. That adage might apply to Humana Inc (NYSE:HUM) stock at this point. Humana stock has gained 259% in the past five years. HUM stock trades just off an all-time high at the moment, thanks to recent bullish speculation.
Upvote Downvote

Medicare Rate Up More than Expected, Health Insurers to Gain

2018-04-03 zacks
The Centers for Medicare and Medicaid Services (“CMS”), a division of the U.S. Department of Health and Human Services, has decided to raise 2019 Medicare Advantage reimbursement rate by 3.4%. Notably, CMS previously proposed a hike of 1.84% in February but this rate increase is higher than expected. Following the announcement, shares of companies with exposure to the MA business like UnitedHealth Group Inc.
Upvote Downvote

Humana's Medicare Advantage Boost Could Cost Walmart - Bloomberg

2018-04-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

High-flying biotech Loxo tempers bullish view for cancer drug

2018-04-03 channelnewsasia
In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer . Its stock tripled in the past year.
Upvote Downvote

FOCUS-High-flying biotech Loxo tempers bullish view for cancer drug

2018-04-03 reuters
STAMFORD, Connecticut (Reuters) - In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany’s Bayer. Its stock tripled in the past year.
Upvote Downvote

Retailers May Shake Healthcare: 4 Stocks for a Fit Portfolio

2018-04-02 zacks
Speculation is rife that retail major Walmart will acquire health insurer Humana. Walmart is not the first retailer showing interest in the healthcare space. Recently, Amazon entered into joint venture with JP Morgan and Berkshire Hathaway to manage insurance for their employees. The company also expressed acute interest in pharmacy business.
Upvote Downvote

Social Seen: Good Charlotte gig, Mr G's birthday and the Golden Slipper

Good Charlotte front men Joel Madden and Benji Madden performing for an intimate crowd on V Island on Sydney Harbour on Tuesday, March 27, 2018.Photo: Oliver Minnett
Upvote Downvote

Anthem Will Dominate Certain Markets

2018-03-27 seekingalpha
Editor's note: Seeking Alpha is proud to welcome Keith Tapper as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
Upvote Downvote

5 Reasons Why Centene is an Attractive Bet for Investors

2018-03-20 zacks
Centene Corporation (CNC - Free Report) is well poised for growth on the back of its recent business-boosting pacts. In March 2018, it has purchased a stake in cloud-based pharmacy benefit manager, RxAdvance, which should help it to lower drug costs and provide improved health care services.
Upvote Downvote

Is Anthem (ANTM) a Great Stock for Value Investors Right Now?

2018-03-20 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
Upvote Downvote

Waiting For The Next Overreaction With Exact Sciences

2018-03-19 seekingalpha
Although first quarter guidance was a little disappointing, Exact Sciences remains on a strong trajectory for Cologuard usage/adoption after a very strong 2017.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 036752103